Shares of TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report) shot up 22.4% during mid-day trading on Friday . The company traded as high as $5.49 and last traded at $5.13. 3,786,615 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 32,220,806 shares. The stock had previously closed at $4.19.
TNF Pharmaceuticals Trading Down 15.6%
The stock has a market capitalization of $8.00 million, a PE ratio of -0.02 and a beta of 2.04. The stock has a 50 day moving average price of $3.79 and a 200-day moving average price of $4.04.
TNF Pharmaceuticals Company Profile
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
Featured Articles
- Five stocks we like better than TNF Pharmaceuticals
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
